{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:13:16Z","timestamp":1790266396651,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,27]]},"DOI":"10.7759\/cureus.55068","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T17:17:08Z","timestamp":1709054228000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond the Benefits: A Case Study on the Complications of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (Euglycemic Diabetic Ketoacidosis (DKA) and Takotsubo Cardiomyopathy)"],"prefix":"10.7759","author":[{"given":"Rand","family":"Sabanci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiz","family":"Saaed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appa","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer BF","year":"2021","unstructured":"Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol. 2021, 16:1284-91. 10.2215\/CJN.17621120","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29652","article-title":"A literature review of the therapeutic perspectives of sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis","volume":"14","author":"Patel K","year":"2022","unstructured":"Patel K, Nair A. A literature review of the therapeutic perspectives of sodium-glucose cotransporter-2 (SGLT2) inhibitor-induced euglycemic diabetic ketoacidosis. Cureus. 2022, 14:e29652. 10.7759\/cureus.29652","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/life13061256","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure-current evidence in special populations","volume":"13","author":"Moady G","year":"2023","unstructured":"Moady G, Ben Gal T, Atar S. Sodium-glucose co-transporter 2 inhibitors in heart failure-current evidence in special populations. Life (Basel). 2023, 13:1256. 10.3390\/life13061256","journal-title":"Life (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-8. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12691\/ajmcr-6-1-1","article-title":"A case of euglycemic diabetic ketoacidosis due to canagliflozin complicated by Takotsubo cardiomyopathy","volume":"6","author":"Khan M","year":"2018","unstructured":"Khan M, Khalid S, Marwat A, Mehmood H. A case of euglycemic diabetic ketoacidosis due to canagliflozin complicated by Takotsubo cardiomyopathy. Am J Med Case Rep. 2018, 6:1-3. 10.12691\/ajmcr-6-1-1","journal-title":"Am J Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata F","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al.. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021, 11:10293. 10.1038\/s41598-021-89752-w","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al.. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022, 400:757-67. 10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/11795468211065782","article-title":"Takotsubo syndrome: a review of presentation, diagnosis and management","volume":"16","author":"Assad J","year":"2022","unstructured":"Assad J, Femia G, Pender P, Badie T, Rajaratnam R. Takotsubo syndrome: a review of presentation, diagnosis and management. Clin Med Insights Cardiol. 2022, 16:11795468211065782. 10.1177\/11795468211065782","journal-title":"Clin Med Insights Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/232182-beyond-the-benefits-a-case-study-on-the-complications-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-euglycemic-diabetic-ketoacidosis-dka-and-takotsubo-cardiomyopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T17:17:10Z","timestamp":1709054230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/232182-beyond-the-benefits-a-case-study-on-the-complications-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-euglycemic-diabetic-ketoacidosis-dka-and-takotsubo-cardiomyopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.55068","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}